KEYNOTE-062

NCT02494583 📎

Regimen

Experimental
pembrolizumab monotherapy, or pembrolizumab + chemotherapy
Control
chemotherapy

Population

First-line PD-L1 CPS>=1 advanced gastric/GEJ adenocarcinoma

Key finding

Pembro vs chemo (CPS>=1) mOS 10.6 vs 11.1 mo noninferior; CPS>=10 17.4 vs 10.8 mo (HR 0.69 NS); pembro+chemo vs chemo NS on OS

Source: PMID 32880601

Timeline

    Guideline citations

    • NCCN GASTRIC (p.45)
    • CSCO GASTRIC 2025 (p.98)⚠️ OCR source